 The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue MALT lymphoma, marginal zone lymphoma MZL or CD5-, CD10-, CD20 low-grade B cell lymphomas. 